OncoMatch/Clinical Trials/NCT04728724
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Is NCT04728724 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sintilimab and Chemotherapy for non-small cell lung cancer stage iii.
Treatment: Sintilimab · Chemotherapy — This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR activating mutation
Non-squamous cell carcinoma with EGFR active mutation positive
Excluded: ALK rearrangement
Non-squamous cell carcinoma with ... ALK rearrangement
Disease stage
Required: Stage III
stage III confirmed by imageological examinations (CT, PET-CT or EBUS); Without systematic metastasis (including M1a, M1b and M1c)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment for thymic epithelial tumor
Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment
Cannot have received: Chinese medicine against cancer
Administration of any Chinese medicine against cancer before administration of the drug
Lab requirements
Blood counts
ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90 g/L; INR and PT < 1.5×ULN; APTT ≤1.5×ULN
Kidney function
Liver function
Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN, or ≤5×ULN in patients with liver metastatic tumor
Patients with good function of other main organs (liver, kidney, blood system, etc.): ... see details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify